Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Genelux Corp (GNLX)

Genelux Corp (GNLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Genelux Corporation CEO Thomas Zindrick to Participate in Virtual Fireside Chat on Clinical Developments for Olvi-Vec

Genelux Corporation's CEO will discuss its lead candidate, Olvi-Vec, in a virtual session on December 16, 2024.Quiver AI SummaryGenelux Corporation, a late clinical-stage immuno-oncology firm, announced...

GNLX : 2.27 (+3.65%)
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

GNLX : 2.27 (+3.65%)
Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates

GNLX : 2.27 (+3.65%)
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference

GNLX : 2.27 (+3.65%)
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

GNLX : 2.27 (+3.65%)
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit

GNLX : 2.27 (+3.65%)
Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GNLX),(NASDAQ:CRNX),(NYSE:PFE),(NASDAQ:SGEN) EQNX::TICKER_END

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
GNLX : 2.27 (+3.65%)
CRNX : 53.60 (+1.63%)
PFE : 26.36 (+2.29%)
SGEN : 228.74 (-0.07%)
Navigating the Surge in Pancreatic Cancer: The Innovative Strategies Offering New Hope

USA News Group – Researchers are becoming increasingly concerned with the rates of cancer on the rise among people under 50. A recent study found a nearly 80% global increase in the number of under-50s...

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
GNLX : 2.27 (+3.65%)
CRNX : 53.60 (+1.63%)
PFE : 26.36 (+2.29%)
SGEN : 228.74 (-0.07%)
Why Shares of Genelux Climbed This Week

The company's shares rose on signs it might be getting closer to its first biologics license application.

GNLX : 2.27 (+3.65%)
Why Shares of Genelux Corporation Jumped This Week

The company reported positive phase 2 trial news regarding its lead therapy.

GNLX : 2.27 (+3.65%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar